Spero Therapeutics has announced it has raised $51.7m in a series C financing round led by GV (formerly Google Ventures).
The funding round also included participation from new investors RA Capital Management and Rock Springs Capital and existing investors Atlas Venture, S.R. One Limited, MRL Ventures Fund, Lundbeckfonden Ventures, The Kraft Group, and Osage University Partners.
Spero is a US-based biopharmaceutical company focused on developing therapies for treating bacterial infections. The company plans to use the funds to advance its anti-bacterials.
BioCryst Pharmaceuticals has announced plans to issue its common stock shares to raise gross proceeds of $45m.
US-based developer of treatments for rare and infectious diseases BioCryst plans to use the funds for general corporate purposes.
Breath Therapeutics Holding has announced the raising of €43.5m ($46.01m) in a series A financing round co-led by Gimv and Sofinnova Partners. The funding round also included participation from Gilde Healthcare Partners.
Based in Germany, Breath Therapeutics is an inhalation therapies provider for severe respiratory diseases. The company plans to use the proceeds for conducting Phase III trials and submitting marketing application.
Bioversys and Aptuit have partnered to develop novel targets and molecules for the treatment of serious infections. The partnership will enable the companies to develop therapies for gram-negative bacteria.
Aptuit will also provide its in-vitro and in-vivo capabilities in infectious disease drug discovery.
Bioversys is a biopharmaceutical company based in Switzerland, while Aptuit is a drug discovery and development services provider based in the US.
NovAliX SAS has announced the signing of a multi-year in-sourcing agreement with Belgian biopharmaceutical company, UCB Biopharma SPRL.
NovAliX will provide on-site discovery chemistry services for small molecules drug discovery programmes, as part of the agreement.
Based in France, NovAliX is a contract research organisation (CRO) focused on drug discovery.